Bone marrow dysfunctions preceding acute leukemia in children: a clinical study

Area of Science:

• Pediatric Hematology Oncology
• Hematologic Malignancies
• Childhood Cancer Research

Background:

• Preleukaemic states, such as myelodysplastic syndromes (MDS), can precede overt acute myeloid leukaemia (AML) in children.
• Specific subgroups, like those with Down's syndrome and the bone marrow monosomy 7 syndrome, are notable.
• Cytogenetic abnormalities are frequent in MDS and often progress with the disease.

Purpose of the Study:

• To review preleukaemic states in children.
• To analyze the characteristics and outcomes of children with MDS preceding AML.
• To discuss treatment considerations and emerging therapies.

Main Methods:

• Prospective review of 109 children with AML.
• Analysis of cases where overt AML was preceded by MDS.
• Review of cytogenetic data and treatment responses.

Main Results:

• MDS preceded overt AML in 22 out of 109 children, with 10 having Down's syndrome.
• Cytogenetic anomalies were common in MDS, becoming more complex as the disease progressed.
• Transformation to overt AML occurred in most cases, with limited survival rates.
• Cytostatic treatment posed a risk of aplasia; bone marrow transplantation showed benefit in a few cases.
• Pre-leukaemic dysfunction preceding acute lymphoblastic leukaemia (ALL) involved transient aplastic anaemia, with ALL responding similarly to de novo cases.

Conclusions:

• Preleukaemic states significantly impact the course and prognosis of childhood leukaemias.
• Careful consideration of treatment strategies, including cytostatic therapy and bone marrow transplantation, is crucial.
• Further research into managing these preleukaemic conditions is warranted to improve outcomes.